Predictors of Recurrence After RNU for Low-Grade UTUC
The findings may inform surveillance strategies and improve treatment outcomes.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Post-RC Radiation Does Not Up Survival in Locally Advanced Bladder Cancer
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Use of 5-ARIs May Decrease Bladder Cancer Risk
A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
UTUC in Octogenarians Frequently Managed Without Surgery
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Prostate, Bladder Cancer Care Delays Common During Pandemic
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Time to Metastasis May Be a Surrogate for UTUC Survival After Surgery
Distant metastasis emerged as the best candidate to be a surrogate endpoint for survival among patients receiving surgical treatment for upper tract urothelial carcinoma.
Cancer Risks, Mortality Vary With CKD Stage
The proportion of patients with chronic kidney disease who die from cancer may be underappreciated.
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue the trials was based on data from preplanned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
‘Overuse’ of Surveillance Testing Observed in Low-Grade Non-Muscle Invasive Bladder Cancer
A large study showed an increase in surveillance testing over time among patients with low-grade Ta non-muscle invasive bladder cancer.
Cutaneous Adverse Effects Common With Enfortumab Vedotin for Urothelial Cancer
Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.
Recovery From Radical Cystectomy Takes Three to Six Months
There was no difference in the percentage of patients recovering at each time point for robot-assisted vs open radical cystectomy.
Radical Cystectomy vs Trimodal Tx for cT3 MIBC May Offer Better Survival
Increasing T stage has been associated with reduced long-term survival after trimodal therapy.
PD-L1 Expression May Help Predict BCG Response in High-Grade NMIBC
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Bladder Cancer Drug Shows Antitumor Activity in Cisplatin-Ineligible Patients
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Prostate Radiation Therapy Does Not Affect BCG Efficacy in NMIBC
Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.
High-Risk NMIBC Effectively Treated With a BCG Alternative
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
Novel Immunotherapy Plus BCG Effective for Unresponsive Bladder Cancer
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma
The median progression-free survival was similar between the treatment arms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...